EuroBiotech: More Articles of Note

newspapers
(Pixabay)

> Enterome teamed up with Memorial Sloan Kettering Cancer Center to assess the use of gut microbiome-derived antigens in cancer. Release 

> 4D pharma presented early data from a trial testing bacterium MRx0518 in combination with Merck’s Keytruda. Two of the first six patients had a “clinically relevant response.” Statement 

> Artios Pharma in-licensed a small-molecule ATR inhibitor developed by MD Anderson Cancer Center and ShangPharma. Release 

> Vaccibody presented early data from a phase 1/2a trial of neoantigen cancer vaccine VB10.NEO. Clinical responses were seen in half of the first 14 patients. Statement

> Oxford Drug Design secured £2.2 million ($2.8 million) to fund work to tackle antimicrobial resistance. Release 

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.